Novel trivalent DNA vaccine for coronavirus and preparation method thereof

By cloning a specific sequence of the novel coronavirus in a eukaryotic expression plasmid and expressing the fusion antigen protein, the interference problem of existing vaccines in multiple protection was solved, and a stronger immune response and virus clearance effect were achieved.

CN120099038BActive Publication Date: 2026-01-09HUBEI UNIV OF MEDICINE
2 Cites 0 Cited by

Patent Information

Application Number
CN202510259096.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2025-03-06
Publication Date
2026-01-09
Estimated Expiration
2045-03-06

AI Technical Summary

Technical Problem

Existing fusion protein vaccines interfere with and inhibit the induction of multiple antibodies and cross-protective immune effects, and cannot achieve multiple protections with a single immunization.

Method used

A trivalent DNA vaccine for the novel coronavirus was designed by cloning target sequences 1, 2, and 3 in the eukaryotic expression plasmid pCI-neo, expressing the fusion antigen protein, and performing expression and mouse immunization experiments in Vero cells to screen recombinant plasmids pCI-TV-RNR1 and pCI-TV-RNR2 to enhance the immune effect.

Benefits of technology

Recombinant plasmids pCI-TV-RNR1 and pCI-TV-RNR2 can generate a variety of antibodies in mice, significantly improving the protective effect against the novel coronavirus. In particular, pCI-TV-RNR2 has a stronger protective effect, with higher T-cell immune response and virus clearance capacity.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present application relates to the technical field of novel coronavirus, and particularly relates to a novel coronavirus trivalent DNA vaccine and a preparation method. The trivalent DNA vaccine takes a recombinant plasmid carrying a nucleotide sequence as shown in SEQ ID NO: 1 or 2 as an active ingredient. The trivalent DNA vaccine provided in the present application can express a fusion antigen protein of three kinds of antigen genes of the novel coronavirus in eukaryotic cells, and produce serum IgG antibodies against the three kinds of antigens of the novel coronavirus. In addition, the novel coronavirus trivalent DNA vaccine provided in the present application can immunize mice to produce T cells secreting various cytokines, and has a stronger T cell immune protection effect.
Need to check novelty before this filing date? Find Prior Art